However, a phase I study (NCT01811992) in newly diagnosed GBM patients revealed an mOS of 21.3 months when AdV-tk was combined with another adenovirus expressing FMS-like tyrosine kinase 3 ligand (Flt3L) [157]. This evidence concerns the gene TKT and glioblastoma.